Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κb-induced inflammation

Nephrology Dialysis Transplantation

Volumn 31, Issue 11, 2016, Pages 1826-1834

  Wu, Ming ^a   Gu, Junhui ^a   Mei, Shuqin ^a   Xu, Dechao ^a   Jing, Ying ^a   Yao, Qing ^a   Chen, Meihan ^a   Yang, Ming ^a   Chen, Sixiu ^a   Yang, Bo ^a   Qi, Na ^a   Hu, Huimin ^a   Wüthrich, Rudolf P ^b   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

autosomal dominant polycystic kidney disease; inflammation; macrophages; mTOR; NF B

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CREATININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; PROTEIN P105; QUINAZOLINE; RESVERATROL; S6 KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; UREA; CCL2 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATTENUATION; BODY WEIGHT; CELL INFILTRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; MACROPHAGE; MALE; MDCK CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; COMPARATIVE STUDY; DOG; INFLAMMATION; METABOLISM; PATHOLOGY; POLYCYSTIC KIDNEY DISEASES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DISEASE PROGRESSION; DOGS; HUMANS; INFLAMMATION; MADIN DARBY CANINE KIDNEY CELLS; MALE; NF-KAPPA B; POLYCYSTIC KIDNEY DISEASES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STILBENES; TUMOR NECROSIS FACTOR-ALPHA; ZEBRAFISH;

EID: 84996598547     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw058     Document Type: Article

References (35)

1. Wilson PD, Goilav B. Cystic disease of the kidney. Annu Rev Pathol 2007; 2: 341-368
2. Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 2014; 124: 2315-2324
3. Wüthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother 2014; 15: 1085-1095
4. Ta MH, Harris DC, Rangan GK. Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology (Carlton) 2013; 18: 317-330
5. Zoja C, Corna D, Locatelli Met al. Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron Physiol 2015; 129: 52-61
6. Li X, Magenheimer BS, Xia S et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 2008; 14: 863-868
7. Swenson-Fields KI, Vivian CJ, Salah SM et al. Macrophages promote polycystic kidney disease progression. Kidney Int 2013; 83: 855-864
8. Karihaloo A, Koraishy F, Huen SC et al.Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22: 1809-1814
9. Su Z, Wang X, Gao X et al. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. J Intern Med 2014; 276: 470-485
10. Mrug M, Zhou J, Guay-Woodford LM et al. Renal macrophages in autosomal recessive polycystic kidney disease. Nephrology (Carlton) 2013; 18: 746
11. Su Z, Wüthrich RP, Mei C. Response to letter from the editor 'Complement C3 activation in cyst fluid and urine from autosomal dominant polycystic kidney disease patients'. J Intern Med 2014; 276: 541-542
12. Mukherjee S, Dudley JI, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010; 8: 478-500
13. Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev 2013; 2013: 568093
14. Saldanha JF, Leal Vde O, Stenvinkel P et al. Resveratrol: why is it a promising therapy for chronic kidney disease patients? Oxid Med Cell Longev 2013; 2013: 963217
15. Wu M, Arcaro A, Varga Z et al. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 2009; 297: F1597-F1605
16. Wu M, Wahl PR, Le Hir M et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259
17. Rangan G, Wang Y, Harris D. NF-κB signalling in chronic kidney disease. Front Biosci (Landmark Ed) 2009; 14: 3496-3522
18. Cao Y, Semanchik N, Lee SH et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc Natl Acad Sci USA 2009; 106: 21819-21824
19. Parker E, Newby LJ, Sharpe CC et al. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int 2007; 72: 157-165
20. Mrug M, Zhou J, Mrug S et al. Complement C3 activation in cyst fluid and urine from autosomal dominant polycystic kidney disease patients. J Intern Med 2014; 276: 539-540
21. Sanz AB, Sanchez-Nino MD, Ramos AM et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262
22. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203-234
23. Nagao S, Morita M, KugitaMet al. Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of Sam-Cystin. Am J Physiol Renal Physiol 2010; 299: F1078-F1086
24. Qin S, Taglienti M, Cai L et al. c-Met and NF-κB-dependent overexpression of Wnt7a and-7b and Pax2 promotes cystogenesis in polycystic kidney disease. J Am Soc Nephrol 2012; 23: 1309-1318
25. Park EY, Seo MJ, Park JH. Effects of specific genes activating RAGE on polycystic kidney disease. Am J Nephrol 2010; 32: 169-178
26. Renaud J, Martinoli MG. Resveratrol as a protective molecule for neuroinflammation: a review of mechanisms. Curr Pharm Biotechnol 2014; 15: 318-329
27. Borriello A, Bencivenga D, Caldarelli I et al. Resveratrol: from basic studies to bedside. Cancer Treat Res 2014; 159: 167-184
28. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl JMed 2010; 363: 820-829
29. Liu M,Wilk SA,Wang A et al. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem 2010; 285: 36387-36394
30. Peterson KM, Franchi F, Loeffler DL et al. Endothelial dysfunction occurs prior to clinical evidence of polycystic kidney disease. Am J Nephrol 2013; 38: 233-240
31. Menon V, Rudym D, Chandra P et al. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 7-13
32. Maser RL, Vassmer D, Magenheimer BS et al. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol 2002; 13: 991-999
33. Kotsis F, Boehlke C, Kuehn EW. The ciliary flow sensor and polycystic kidney disease. Nephrol Dial Transplant 2013; 28: 518-526
34. Lattke M, Magnutzki A, Walther P et al. Nuclear factor κB activation impairs ependymal ciliogenesis and links neuroinflammation to hydrocephalus formation. J Neurosci 2012; 32: 11511-11523
35. Vezina A, Vaillancourt-Jean E, Albarao S et al. Mesenchymal stromal cell ciliogenesis is abrogated in response to tumor necrosis factor-alpha and requires NF-κB signaling. Cancer Lett 2014; 345: 100-105